Chemomab Therapeutics (NASDAQ:CMMB) Issues Earnings Results, Misses Expectations By $0.23 EPS

Chemomab Therapeutics (NASDAQ:CMMB) released its quarterly earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.23), Zacks reports.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock traded up $0.01 during trading hours on Wednesday, hitting $1.92. The company’s stock had a trading volume of 2,063 shares, compared to its average volume of 89,670. The stock has a 50 day moving average of $1.71 and a 200 day moving average of $1.71. Chemomab Therapeutics has a 12 month low of $1.35 and a 12 month high of $4.12. The company has a market capitalization of $13.85 million, a PE ratio of -0.87 and a beta of 0.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new stake in Chemomab Therapeutics stock. XTX Topco Ltd purchased a new stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned 0.31% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.